Patents by Inventor Pratima Chaurasia

Pratima Chaurasia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enriched and expanded human cord blood stem cells for treatment of hematological disorders
    Patent number: 11261429
    Abstract: This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD1 84+, CD1 17+, CD49f+, ALDH+, CD45RA? and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: March 1, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Pratima Chaurasia, Ronald Hoffman
  • ENRICHED AND EXPANDED HUMAN CORD BLOOD STEM CELLS FOR TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20160097036
    Abstract: This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD1 84+, CD1 17+, CD49f+, ALDH+, CD45RA? and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 7, 2016
    Inventors: Pratima CHAURASIA, Ronald HOFFMAN
  • INDUCTION AND/OR MAINTENANCE OF TUMOR DORMANCY BY DISRUPTION OF UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-INTEGRIN INTERACTION
    Publication number: 20100249184
    Abstract: The present invention relates to a method of inducing cancer cells into dormancy and treating cancer in a subject. This method involves administering to a subject an effective amount of a compound that disrupts interaction between urokinase plasminogen activator receptor and integrin, thereby including cancer cells into dormancy and treating cancer in the subject. Also disclosed is a method of disrupting interaction between integrin and urokinase plasminogen activator receptor on cancer cells. The present invention also relates to a method of screening for compounds effective in inducing tumor dormancy and treating cancer in a subject.
    Type: Application
    Filed: March 17, 2008
    Publication date: September 30, 2010
    Applicants: MOUNT SINAI SCHOOL OF MEDICINE, COPENHAGEN HOSPITAL CORPORATION
    Inventors: Liliana Ossowski, Pratima Chaurasia, Julio A. Aguirre-Ghiso, Ming-Ming Zhou, Michael Ploug